Literature DB >> 22477370

Early thrombosis in bovine mesenteric vein grafts after infrainguinal reconstruction.

Sinasi Manduz1, Nurkay Katrancioglu, Emre Ozker, Kasim Dogan.   

Abstract

INTRODUCTION: Autologous vein grafts are still the gold standard in infrainguinal arterial bypass grafting procedures. However, due to the unavailability of suitable autologous vein grafts, heterogeneous grafts are usually preferred. In the present study, surgical outcomes with bovine mesenteric vein grafts (ProCol, Hancock Jaffe Laboratories, USA) in the infrainguinal location in patients with ischemic leg infection or necrosis are presented.
METHODS: Seven patients who underwent infrainguinal arterial reconstructions with ProCol grafts were evaluated retrospectively.
RESULTS: Graft thrombosis was seen in two patients on postoperative day 1 (28.5%). The shortest and the longest patency durations were six and 18 months, respectively. Aneurysmal dilation developed postoperatively in two grafts (28.5%) after 12 and 18 months, respectively.
CONCLUSION: In cases where infection accompanies ischemia, and autologous veins are not available as graft materials, ProCol grafts can be used as temporary grafts in infrainguinal arterial reconstructions. The use of the graft is believed to be unacceptable for any indication other than infection due to its low short- and long-term patency rates and high risk of aneurysm formation in this location.

Entities:  

Keywords:  Bovine mesenteric vein graft; Early graft thrombosis; Infrainguinal reconstruction

Year:  2008        PMID: 22477370      PMCID: PMC2728373          DOI: 10.1055/s-0031-1278278

Source DB:  PubMed          Journal:  Int J Angiol        ISSN: 1061-1711


  7 in total

1.  Glutaraldehyde-tanned bovine carotid artery graft for infrainguinal vascular reconstruction: 5-year follow-up.

Authors:  R J Holdsworth; S Naidu; P Gervaz; P T McCollum
Journal:  Eur J Vasc Endovasc Surg       Date:  1997-09       Impact factor: 7.069

2.  Systemic pulmonary artery shunt using a bovine mesenteric venous graft in newborns.

Authors:  A Kalangos; M Beghetti; J C Pache; D Vala; B Faidutti
Journal:  J Card Surg       Date:  2000 Jul-Aug       Impact factor: 1.620

3.  The modified bovine arterial graft.

Authors:  N Rosenberg
Journal:  Arch Surg       Date:  1972-10

4.  Results of a bovine collagen vascular graft (Solcograft-P) in infra-inguinal positions.

Authors:  A Schröder; H Imig; U Peiper; J Neidel; A Petereit
Journal:  Eur J Vasc Surg       Date:  1988-10

5.  Outcome of ProCol, a bovine mesenteric vein graft, in infrainguinal reconstruction.

Authors:  A J Kovalic; D K Beattie; A H Davies
Journal:  Eur J Vasc Endovasc Surg       Date:  2002-12       Impact factor: 7.069

6.  Bovine mesenteric vein graft (ProCol) in critical limb ischaemia with tissue loss and infection.

Authors:  J Schmidli; H Savolainen; G Heller; M K Widmer; U Then-Schlagau; I Baumgartner; T P Carrel
Journal:  Eur J Vasc Endovasc Surg       Date:  2004-03       Impact factor: 7.069

7.  Polytetrafluoroethylene and bovine mesenterial vein grafts for hemodialysis access: a comparative study.

Authors:  V B Tahami; H Hakki; P U Reber; M K Widmer; H W Kniemeyer
Journal:  J Vasc Access       Date:  2007 Jan-Mar       Impact factor: 2.283

  7 in total
  2 in total

Review 1.  Stem Cell Sources and Graft Material for Vascular Tissue Engineering.

Authors:  Dorothee Hielscher; Constanze Kaebisch; Benedikt Julius Valentin Braun; Kevin Gray; Edda Tobiasch
Journal:  Stem Cell Rev Rep       Date:  2018-10       Impact factor: 5.739

2.  Bioengineered human acellular vessels for dialysis access in patients with end-stage renal disease: two phase 2 single-arm trials.

Authors:  Jeffrey H Lawson; Marc H Glickman; Marek Ilzecki; Tomasz Jakimowicz; Andrzej Jaroszynski; Eric K Peden; Alison J Pilgrim; Heather L Prichard; Malgorzata Guziewicz; Stanisław Przywara; Jacek Szmidt; Jakub Turek; Wojciech Witkiewicz; Norbert Zapotoczny; Tomasz Zubilewicz; Laura E Niklason
Journal:  Lancet       Date:  2016-05-14       Impact factor: 79.321

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.